Matteo Tozzi, Jan De Letter, Dainis Krievins, Janis Jushinskis, Annick D'Haeninck, Kestutis Rucinskas, Marius Miglinas, Tomas Baltrunas, Sigi Nauwelaers, An S De Vriese, Frans Moll, Frank Vermassen
OBJECTIVE: The creation of an arteriovenous fistula (AVF) is considered the most effective hemodialysis (HD) vascular access. For patients who are not suitable for AVF, arteriovenous grafts (AVGs) are the best access option for chronic HD. However, conventional AVGs are prone to intimal hyperplasia, stenosis, thrombosis, and infection. Xeltis has developed an AVG as a potential alternative to currently available AVGs based on the concept of endogenous tissue restoration. The results of the first 6-month follow-up are presented here...
February 5, 2024: Journal of Vascular Access